Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

13 Feb 2017

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Anomalies and Fetal Surgery
Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 28192393
DOI: 10.1038/nn.4508

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyPMID 28192393Read ↗

NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in MiceSemantic proximity Read ↗

The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular AtrophySemantic proximity Read ↗

Nusinersen in the Treatment of Spinal Muscular Atrophy.Semantic proximity Read ↗

Nusinersen as a Therapeutic Agent for Spinal Muscular AtrophySemantic proximity Read ↗

RNA-targeted drugs for neuromuscular diseasesSemantic proximity Read ↗

Antisense Oligonucleotide-Based Therapy for Neuromuscular DiseaseSemantic proximity Read ↗

Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and ShadeSemantic proximity Read ↗

Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shadeSemantic proximity Read ↗

FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating OligonucleotidesSemantic proximity Read ↗

Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapySemantic proximity Read ↗

Therapeutic antisense oligonucleotides for movement disordersSemantic proximity Read ↗

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotidesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.